Bliss GVS Pharma (BOM:506197) Cyclically Adjusted Revenue per Share: ₹97.18 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:506197 Bliss GVS Pharma Ltd BOM:506197
58 GF Score
Price ₹587.05
GF Value ₹170.48
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Bliss GVS Pharma Cyclically Adjusted Revenue per Share?

Bliss GVS Pharma BOM:506197 +5.00% 58 Cyclically Adjusted Revenue per Share is ₹97.18 as of Jun. 2026. GuruFocus rates BOM:506197 with a GF Score™ of 58/100 and a GF Value™ of ₹170.48 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Bliss GVS Pharma's adjusted revenue per share for the three months ended in Jun. 2026 was ₹26.507. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹97.18 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Bliss GVS Pharma's average Cyclically Adjusted Revenue Growth Rate was 4.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 3.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Bliss GVS Pharma was 3.30% per year. The lowest was 3.00% per year. And the median was 3.15% per year.

As of today (2026-08-31), Bliss GVS Pharma's current stock price is ₹587.05. Bliss GVS Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹97.18. Bliss GVS Pharma's Cyclically Adjusted PS Ratio of today is 6.04.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bliss GVS Pharma was 6.04. The lowest was 0.81. And the median was 1.31.


Bliss GVS Pharma  (BOM:506197) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Bliss GVS Pharma's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=587.05/97.18
=6.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bliss GVS Pharma was 6.04. The lowest was 0.81. And the median was 1.31.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Bliss GVS Pharma Cyclically Adjusted Revenue per Share Related Terms


Bliss GVS Pharma Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Bliss GVS Pharma's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bliss GVS Pharma Cyclically Adjusted Revenue per Share Chart

Bliss GVS Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 83.63 86.66 89.98 91.51 95.58

Bliss GVS Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 93.27 94.31 94.86 95.58 97.18

BOM:506197 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Bliss GVS Pharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bliss GVS Pharma Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bliss GVS Pharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Bliss GVS Pharma's Cyclically Adjusted PS Ratio falls into.


BOM:506197
58GF Score
Bliss GVS Pharma Ltd BOM:506197
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bliss GVS Pharma Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Bliss GVS Pharma's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=26.507/167.3573*167.3573
=26.507

Current CPI (Jun. 2026) = 167.3573.

Bliss GVS Pharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 28.235 105.961 44.595
201612 22.486 105.196 35.773
201703 24.962 105.196 39.712
201706 21.527 107.109 33.636
201709 21.938 109.021 33.677
201712 19.020 109.404 29.095
201803 16.241 109.786 24.758
201806 23.721 111.317 35.663
201809 22.151 115.142 32.196
201812 21.330 115.142 31.003
201903 22.510 118.202 31.871
201906 20.533 120.880 28.428
201909 20.347 123.175 27.645
201912 14.320 126.235 18.985
202003 10.904 124.705 14.633
202006 12.321 127.000 16.236
202009 12.321 130.118 15.847
202012 15.603 130.889 19.950
202103 11.662 131.771 14.812
202106 15.876 134.084 19.816
202109 18.524 135.847 22.821
202112 20.844 138.161 25.249
202203 14.624 138.822 17.630
202206 17.898 142.347 21.043
202209 16.554 144.661 19.151
202212 19.436 145.763 22.315
202303 17.211 146.865 19.613
202306 14.991 150.280 16.695
202309 19.932 151.492 22.019
202312 18.901 152.924 20.685
202403 18.310 153.035 20.024
202406 17.124 155.789 18.396
202409 20.547 157.882 21.780
202412 20.067 158.323 21.212
202503 18.602 157.552 19.760
202506 19.475 159.755 20.402
202509 22.780 162.289 23.491
202512 20.075 163.281 20.576
202603 23.622 164.272 24.066
202606 26.507 167.357 26.507

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹97.18 mean?
Bliss GVS Pharma (BOM:506197) has a Cyclically Adjusted Revenue per Share of ₹97.18 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bliss GVS Pharma and its competitors.
Is Bliss GVS Pharma's Cyclically Adjusted Revenue per Share too high?
Bliss GVS Pharma's current Cyclically Adjusted Revenue per Share is ₹97.18. Overall, Bliss GVS Pharma has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bliss GVS Pharma's Cyclically Adjusted Revenue per Share compare to ZTS?
Bliss GVS Pharma's Cyclically Adjusted Revenue per Share of ₹97.18 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bliss GVS Pharma and its competitors. Bliss GVS Pharma's current Cyclically Adjusted Revenue per Share is ₹97.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bliss GVS Pharma stock overvalued right now?
Based on GuruFocus' analysis, Bliss GVS Pharma (BOM:506197) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹170.48, compared to a current price of ₹587.05 — trading 244.4% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹97.18. Bliss GVS Pharma's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Bliss GVS Pharma (BOM:506197), the current Cyclically Adjusted Revenue per Share is ₹97.18 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bliss GVS Pharma (BOM:506197) Overvalued in 2026?

Based on GuruFocus' analysis, Bliss GVS Pharma stock appears to be overvalued. The current stock price of ₹587.05 is trading 244.4% above its estimated GF Value™ of ₹170.48. GuruFocus considers Bliss GVS Pharma to be Significantly Overvalued.

Key valuation signals for BOM:506197:

  • Cyclically Adjusted Revenue per Share: ₹97.18
  • GF Value™: ₹170.48 vs. price of ₹587.05 (244.4% above fair value)
  • GF Score™: 58/100 with 5 warning signs

No single metric tells the full story. See the BOM:506197 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bliss GVS Pharma Business Description

Other Exchanges BLISSGVS:India
Address Saki Vihar Road, 102, Hyde Park, Andheri (East), Mumbai, MH, IND, 400072
Bliss GVS Pharma Ltd is an India-based company engaged in the manufacturing, marketing, trading, and export of pharmaceutical products. Some of its brands include Lonart, P-Alaxin, Funbact, and Lofnac, and others. It offers pharma products including tablets, suspensions, suppositories, and injections. The majority of its revenue is derived from Exports.
58GF Score

Get the complete analysis for BOM:506197

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹587.05
Price
₹170.48
GF Value